Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart surgery

Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting (CABG) or heart valve replacement: a triple-blind, randomized, placebo-controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120520009801N9

Enrollment

160

Registered

2022-12-07

Start date

2022-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation after heart surgery. Paroxysmal atrial fibrillation

Interventions

Intervention 1: Intervention group: It includes patients who receive 10 mg empagliflozin tablets made by abidi under the brand name Gloripa once daily for three days before to three days after surgery

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Candidates for heart surgery including CABG or valve replacement 70 yr > age > 18 yr Taking ACEIs/ARBs, beta-blockers, statins and aspirin for CABG patients

Exclusion criteria

Exclusion criteria: History of taking empagliflozin drug before surgery Severe heart failure (NYHA Class IV) Renal failure (30 = GFR) Hepatic failure (hepatic enzymes > 3 times of upper normal limit ) pregnancy Have pacemaker Have AF rhythm History of heart surgery Very thin people (BMI = 18.5 kg/m2)

Design outcomes

Primary

Measure	Time frame
The incidence of atrial fibrillation. Timepoint: Through 72 hrs after heart surgery. Method of measurement: Holter monitoring.	—

Secondary

Measure	Time frame
C-Reactive Protein (CRP) blood concentration. Timepoint: Before surgery and 3 days after surgery. Method of measurement: Laboratory.;The incidence of ventricular and supra-ventricular arrhythmias. Timepoint: Through 72 hrs after heart surgery. Method of measurement: Holter monitoring.;Lenght of hospital stay. Timepoint: From heart surgery to discharge. Method of measurement: Counting of hospitalizations days.	—

Measure

Time frame

C-Reactive Protein (CRP) blood concentration. Timepoint: Before surgery and 3 days after surgery. Method of measurement: Laboratory.;The incidence of ventricular and supra-ventricular arrhythmias. Timepoint: Through 72 hrs after heart surgery. Method of measurement: Holter monitoring.;Lenght of hospital stay. Timepoint: From heart surgery to discharge. Method of measurement: Counting of hospitalizations days.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBatool Zarei

Mashhad University of Medical Sciences

zareb982@mums.ac.ir+98 51 3180 1100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026